ATYR

Bearish

aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48

This article reports a significant decrease in the price target for aTyr Pharma (ATYR) shares. The new target is $6.48, representing a 37.13% reductio...

MSN 2 days ago 0

Neutral

aTyr Pharma (NASDAQ: ATYR) details Q1 2026 loss and Phase 3 plan

aTyr Pharma reported a net loss of $10.8 million for Q1 2026, an improvement from $14.9 million in Q1 2025. The company plans to submit an Investigati...

Stock Titan 2 weeks ago 0

Bullish

Biotech plans global lung disease trial after FDA talks, holds $68M cash

aTyr Pharma reported Q1 2026 results, ending March 31, 2026, with $68.3 million in cash. The company plans to file an IND in June 2026 for a new globa...

Stock Titan 2 weeks ago 0

Neutral

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma (NASDAQ: ATYR) announced its first quarter 2026 results and provided a corporate update, including a clear path forward for efzofitimod in...

Yahoo! Finance Canada 2 weeks ago 0